Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Oxcarbazepine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 0.41 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.41 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.89 |
| ▸ | MAPT | P10636 | 2/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.89 |
| ▸ | MEN1 | O00255 | 2/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.89 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.89 |
| ▸ | BLM | P54132 | 1/20 | 0.89 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxcarbazepine SCHEMBL29359799 | 0.94 | KDM4E (1.00) | KDM4EALDH1A1MAPTCYP3A4MEN1 | |
| Oxcarbazepine SCHEMBL35129 | 0.94 | KDM4E (1.00) | KDM4EALDH1A1MAPTCYP3A4MEN1 | |
| Oxcarbazepine SCHEMBL4655725 | 0.94 | KDM4E (1.00) | KDM4EALDH1A1MAPTCYP3A4MEN1 | |
| Oxcarbazepine SCHEMBL29433241 | 0.94 | KDM4E (1.00) | KDM4EALDH1A1MAPTCYP3A4MEN1 | |
| Oxcarbazepine SCHEMBL17372732 | 0.93 | KDM4E (0.97) | KDM4EALDH1A1MAPTCYP3A4MEN1 | |
| Oxcarbazepine SCHEMBL27944289 | 0.93 | KDM4E (0.97) | KDM4EALDH1A1MAPTCYP3A4MEN1 | |
| Oxcarbazepine SCHEMBL2885435 | 0.89 | KDM4E (0.89) | KDM4EALDH1A1MAPTCYP3A4MEN1 | |
| Oxcarbazepine SCHEMBL29123953 | 0.89 | ALDH1A1 (0.89) | KDM4EALDH1A1MAPTCYP3A4MEN1 | |
| Oxcarbazepine SCHEMBL2328082 | 0.86 | KDM4E (0.84) | KDM4EALDH1A1MAPTCYP3A4MEN1 | |
| Oxcarbazepine SCHEMBL321371 | 0.86 | KDM4E (0.84) | KDM4EALDH1A1MAPTCYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183272-B2 | Crystal forms of oxcarbazepine and processes for their preparation | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-02-27 | — | — | US | claimed |
| EP-1368322-A4 | NEW CRYSTAL FORMS OF OXCARBAZEPINE AND PROCESSES FOR THEIR PREPARATION | TEVA PHARMA (IL) | 2004-03-17 | — | — | EP | claimed |
| EP-1368322-A2 | NEW CRYSTAL FORMS OF OXCARBAZEPINE AND PROCESSES FOR THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-12-10 | — | — | EP | claimed |
| US-20030004154-A1 | New crystal forms of oxcarbazepine and processes for their preparation | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-01-02 | — | — | US | claimed |
| WO-2002064557-A9 | NEW CRYSTAL FORMS OF OXCARBAZEPINE AND PROCESSES FOR THEIR PREPARATION | TEVA PHARMA (IL) | 2002-11-28 | — | — | WO | claimed |
| WO-2002064557-A2 | NEW CRYSTAL FORMS OF OXCARBAZEPINE AND PROCESSES FOR THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-08-22 | — | — | WO | claimed |
| US-7183272-B2 | Crystal forms of oxcarbazepine and processes for their preparation | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-02-27 | — | — | US | disclosed |
| EP-1368322-A4 | NEW CRYSTAL FORMS OF OXCARBAZEPINE AND PROCESSES FOR THEIR PREPARATION | TEVA PHARMA (IL) | 2004-03-17 | — | — | EP | disclosed |
| EP-1368322-A2 | NEW CRYSTAL FORMS OF OXCARBAZEPINE AND PROCESSES FOR THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-12-10 | — | — | EP | disclosed |
| US-20030004154-A1 | New crystal forms of oxcarbazepine and processes for their preparation | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-01-02 | — | — | US | disclosed |
| WO-2002064557-A9 | NEW CRYSTAL FORMS OF OXCARBAZEPINE AND PROCESSES FOR THEIR PREPARATION | TEVA PHARMA (IL) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002064557-A2 | NEW CRYSTAL FORMS OF OXCARBAZEPINE AND PROCESSES FOR THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004154-A1 | New crystal forms of oxcarbazepine and processes for their preparation | CACNA1C, CACNA1B, TBCB | SCN4A 645/4885SCN5A 729/4885SCN9A 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.